Achieve Life Sciences, Inc.
US ˙ NasdaqCM ˙ US0044685008

Introduction

This page provides a comprehensive analysis of the known insider trading history of David V Smith. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David V Smith has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CDXS / Codexis, Inc. Director 105,705
US:IOBT / IO Biotech, Inc. Director 28,019
Executive Vice President & CFO 0
US:ACHV / Achieve Life Sciences, Inc. Director 22,500
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David V Smith. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACHV / Achieve Life Sciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACHV / Achieve Life Sciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACHV / Achieve Life Sciences, Inc. Insider Trades
Insider Sales ACHV / Achieve Life Sciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACHV / Achieve Life Sciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACHV / Achieve Life Sciences, Inc. Insider Trades
Insider Purchases CDXS / Codexis, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACHV / Achieve Life Sciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CDXS / Codexis, Inc. Insider Trades
Insider Sales CDXS / Codexis, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACHV / Achieve Life Sciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CDXS / Codexis, Inc. Insider Trades
Insider Purchases IOBT / IO Biotech, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACHV / Achieve Life Sciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOBT / IO Biotech, Inc. Insider Trades
Insider Sales IOBT / IO Biotech, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACHV / Achieve Life Sciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOBT / IO Biotech, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David V Smith as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-12 2025-06-10 4 CDXS CODEXIS, INC.
Common Stock
A - Award 40,983 105,705 63.32
2024-06-13 2024-06-11 4 CDXS CODEXIS, INC.
Common Stock
A - Award 30,120 64,722 87.05
2023-06-15 2023-06-13 4 CDXS CODEXIS, INC.
Common Stock
A - Award 34,602 34,602
2023-06-15 2023-06-13 4 CDXS CODEXIS, INC.
Common Stock
G - Gift -11,273 0 -100.00
2022-06-16 2022-06-14 4 CDXS CODEXIS, INC.
Common Stock
A - Award 11,273 11,273
2022-06-16 2022-06-14 4 CDXS CODEXIS, INC.
Common Stock
G - Gift -4,796 0 -100.00
2022-03-03 2022-03-01 4 IOBT IO Biotech, Inc.
Stock Option (Right to Buy)
A - Award 28,019 28,019
2022-01-14 2021-09-15 5 CDXS CODEXIS, INC.
Common Stock
G - Gift -4,000 72,501 -5.23
2021-06-17 2021-06-15 4 CDXS CODEXIS, INC.
Common Stock
A - Award 4,796 4,796
2021-06-17 2021-06-15 4 CDXS CODEXIS, INC.
Common Stock
G - Gift -8,952 0 -100.00
2021-04-19 2021-04-16 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Employee Stock Option (right to buy)
D - Sale to Issuer -90,000 0 -100.00
2021-04-19 2021-04-16 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Employee Stock Option (right to buy)
D - Sale to Issuer -90,000 0 -100.00
2021-04-19 2021-04-16 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Employee Stock Option (right to buy)
D - Sale to Issuer -185,000 0 -100.00
2021-04-19 2021-04-16 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
D - Sale to Issuer -138,947 0 -100.00 38.00 -5,279,986
2021-04-19 2021-04-16 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
A - Award 66,000 138,947 90.48
2021-02-26 2021-02-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
F - Taxes -5,110 72,947 -6.55 25.71 -131,378 1,875,467
2020-12-15 2020-12-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Performance-Based Restricted Common Stock
M - Exercise -22,000 0 -100.00
2020-12-15 2020-12-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
F - Taxes -11,504 78,057 -12.84 16.14 -185,675 1,259,840
2020-12-15 2020-12-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
M - Exercise 22,000 89,561 32.56
2020-11-30 2020-11-26 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
F - Taxes -6,920 67,561 -9.29 18.45 -127,674 1,246,500
2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Performance-Based Restricted Common Stock
M - Exercise -22,000 22,000 -50.00
2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
F - Taxes -10,908 74,481 -12.77 18.00 -196,344 1,340,658
2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
M - Exercise 22,000 85,389 34.71
2020-06-18 2020-06-16 4 CDXS CODEXIS, INC.
Common Stock
A - Award 8,952 8,952
2020-06-18 2020-06-11 4 CDXS CODEXIS, INC.
Common Stock
G - Gift -4,947 0 -100.00
2020-03-11 2020-02-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Employee Stock Option (right to buy)
A - Award 90,000 90,000
2020-03-11 2020-02-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Employee Stock Option (right to buy)
A - Award 90,000 90,000
2020-03-11 2020-02-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
A - Award 15,000 63,389 31.00
2020-03-11 2020-02-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
A - Award 15,000 63,389 31.00
2019-11-27 2019-11-26 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock
F - Taxes -6,611 33,389 -16.53 3.77 -24,923 125,877
2019-06-26 2019-06-24 4 FPRX FIVE PRIME THERAPEUTICS INC
Performance-Based Restricted Common Stock
A - Award 44,000 44,000
2019-06-13 2019-06-11 4 CDXS CODEXIS INC
Common Stock
A - Award 4,947 4,947
2018-11-27 2018-11-26 4 FPRX FIVE PRIME THERAPEUTICS INC
Employee Stock Option (right to buy)
A - Award 185,000 185,000
2018-11-27 2018-11-26 4 FPRX FIVE PRIME THERAPEUTICS INC
Common Stock
A - Award 40,000 40,000
2018-06-12 2018-06-11 4 CDXS CODEXIS INC
Common Stock
A - Award 5,923 5,923
2018-04-05 2018-04-03 4 CDXS CODEXIS INC
Common Stock
S - Sale X -6,000 56,679 -9.57 10.37 -62,213 587,693
2017-06-16 2017-06-14 4 CDXS CODEXIS INC
Common Stock
A - Award 17,894 62,679 39.96
2016-06-17 2016-06-15 4 CDXS CODEXIS INC
Common Stock
A - Award 20,094 44,785 81.38
2016-05-27 2016-05-26 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 22,500 22,500
2016-05-24 2016-05-20 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit (RSU)
M - Exercise -2,500 0 -100.00
2016-05-24 2016-05-20 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Common Stock
M - Exercise 2,500 9,500 35.71
2016-03-03 2016-03-01 4 CDXS CODEXIS INC
Common Stock
A - Award 24,691 24,691
2015-05-22 2015-05-21 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit (RSU)
A - Award 2,500 2,500
2015-05-22 2015-05-21 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 5,000 5,000
2015-05-22 2015-05-20 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit (RSU)
M - Exercise -2,500 0 -100.00
2015-05-22 2015-05-20 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Common Stock
M - Exercise 2,500 7,000 55.56
2014-06-09 2014-06-05 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit (RSU)
A - Award 2,500 2,500
2014-06-09 2014-06-05 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 5,000 5,000
2014-06-09 2014-06-05 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit (RSU)
M - Exercise -2,500 0 -100.00
2014-06-09 2014-06-05 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Common Stock
M - Exercise 2,500 4,500 125.00
2013-05-28 2013-05-24 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit (RSU)
A - Award 2,500 2,500
2013-05-28 2013-05-24 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 5,000 5,000
2013-05-28 2013-05-23 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit (RSU)
M - Exercise 0 0
2013-05-28 2013-05-23 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Common Stock
M - Exercise 2,000 2,000 10.64 21,280 21,280
2012-06-04 2012-05-31 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Restricted Stock Unit
A - Award 2,000 2,000
2012-06-04 2012-05-31 4 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 4,000 4,000
2012-02-07 2011-05-26 5 OGXI ONCOGENEX PHARMACEUTICALS, INC.
Stock Options (right to buy)
A - Award 3,500 3,500
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)